The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2013

Filed:

Jul. 25, 2008
Applicants:

David A. Claremon, Maple Glen, PA (US);

Wei He, Audubon, PA (US);

Gerard Mcgeehan, Garnet Valley, PA (US);

Suresh B. Singh, Kendall Park, NJ (US);

Colin M. Tice, Ambler, PA (US);

Zhenrong Xu, Horsham, PA (US);

Yuanjie YE, Ambler, PA (US);

Wei Zhao, Eagleville, PA (US);

Linghang Zhuang, Chalfont, PA (US);

Salvacion Cacatian, Blue Bell, PA (US);

Katerina Leftheris, Skillman, NJ (US);

Inventors:

David A. Claremon, Maple Glen, PA (US);

Wei He, Audubon, PA (US);

Gerard McGeehan, Garnet Valley, PA (US);

Suresh B. Singh, Kendall Park, NJ (US);

Colin M. Tice, Ambler, PA (US);

Zhenrong Xu, Horsham, PA (US);

Yuanjie Ye, Ambler, PA (US);

Wei Zhao, Eagleville, PA (US);

Linghang Zhuang, Chalfont, PA (US);

Salvacion Cacatian, Blue Bell, PA (US);

Katerina Leftheris, Skillman, NJ (US);

Assignee:

Vitae Pharmaceuticals, Inc., Fort Washington, PA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/10 (2006.01); C07D 413/04 (2006.01); C07D 241/04 (2006.01); A61K 31/675 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01);
U.S. Cl.
CPC ...
Abstract

Disclosed are compounds represented by Formula (I): or pharmaceutically acceptable salts, enantiomers or diastereomers thereof. Also disclosed are pharmaceutical compositions comprising the compounds of Formula (I) or pharmaceutically acceptable salts, enantiomers or diastereomers thereof and methods of inhibiting 11β-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Values for the variables in Formula (I) are defined herein.


Find Patent Forward Citations

Loading…